Pharma major, Lupin announced that it has received final approval for its Bimatoprost Ophthalmic Solution, 0.03% from the United States Food and Drugs Administration (FDA) to market a generic version of Allergan Lumigan Ophthalmic Solution, 0.03%.

Lupin Pharmaceuticals (LPI), the company's US subsidiary would commence marketing the product shortly.

Lupin's Bimatoprost Ophthalmic Solution, 0.03% is the AT rated generic equivalent of Lumigan Ophthalmic Solution, 0.03% and is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

Shares of the company declined Rs 45.75, or 2.71%, to trade at Rs 1,645.20. The total volume of shares traded was 113,325 at the BSE (2.15 p.m., Monday).